 CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 09, 2021 GLOBE NEWSWIRE -- Centogene N.V. Nasdaq: CNTG, a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced today a significant milestone in its Rostock International Parkinsons Disease ROPAD Study, with the recruitment and genetic testing of 10,000 participants. Including more than 120 study sites around the world, CENTOGENE is leading the largest study of its kind a global observational study focusing on the role of genetics in Parkinsons disease PD. 